XML 34 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2012
Commitments and Contingencies [Abstract]  
Schedule of future minimum annual payments
As of December 31, 2012, future minimum annual payments under all operating lease agreements are as follows:

Years ending December 31,
 
Minimum
Annual Payments
 
2013
 
$
2,410
 
2014
  
2,410
 
2015
  
2,470
 
2016
  
2,532
 
2017
  
2,595
 
Thereafter
  
8,182
 
Total
 
$
20,599
 
Schedule of licensing, service and supply agreements
Agreement
 
 
Paid from inception to December 31, 2012
  
Future (1)
Commitments
 
Terms
 
Progenics agreements with:
 
 
  
 
    
Lonza Sales AG
 
$
909
  
$
808
 
Annual license fee payments, milestones and royalties, as applicable, in respect of oncology and other products.
 
        
    
PSMA LLC agreements with:
Seattle Genetics, Inc.
  
4,400
   
13,800
 
Milestone and periodic maintenance payments to use ADC technology to link chemotherapeutic agents to monoclonal antibodies that target prostate specific membrane antigen. ADC technology is based in part on technology licensed by SGI from third parties.
 
        
    
Amgen Fremont, Inc. (formerly Abgenix)
  
1,350
   
5,750
 
Milestones and royalties to use XenoMouse® technology for generating fully human antibodies to PSMA LLC's PSMA antigen.
 
        
    
Former member of PSMA LLC
  
241
   
52,216
 
Annual minimum royalty payments and milestones to use technology related to PSMA.

(1) Amounts based on known contractual obligations as specified in the respective license agreements, which are dependent on the achievement or occurrence of future milestones or events and exclude amounts for royalties which are dependent on future sales and are unknown.